Ruizhi Pharmaceutical Technology Co., Ltd. (stock abbreviation: Ruizhi Pharmaceutical, stock code: 300149) is driven by biotechnology innovation and focuses on the fields of pharmaceutical research and development, production service outsourcing and microecological medical care.

Ruizhi Pharmaceutical provides integrated services covering the stages of biopharmaceuticals and chemical drugs from early drug discovery to drug development and large-scale production, and realizes the standardization and precision of microecological medical care. and human microecology health management. Ruizhi Pharmaceutical is committed to becoming the world's advanced CRO&CDMO partner and a global full-life cycle integrated solution provider for pharmaceutical innovation.

Ruizhi Pharmaceutical has 5 national high-tech enterprises and cultivates a professional scientific research service team, including more than 2,000 scientific researchers. The headquarters is located in Shanghai, China, and has established research institutes, laboratories, production bases and operating entities in the United States, Denmark, Hong Kong, Shanghai, Guangzhou, Chengdu, Jiangmen and other places. The sales service network covers five continents around the world.

Ruizhi Pharmaceutical adheres to the development concept of "technology-based and technology-first" and the corporate vision of "becoming a global advanced pharmaceutical and health innovation service enterprise", helps China's pharmaceutical industry innovation and upgrading, and continues to empower the innovation of the global pharmaceutical and health industry, and for the world. Innovative drug services continue to provide the driving force for innovative R&D.